TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis
Brief Summary: This Phase 3 study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day as monotherapy in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 Rheumatoid Arthritis studies.


Options:
A: * Rheumatoid Arthritis (RA) for greater than 1 year from the time of initial diagnosis of RA.
* Participants must have been taking methotrexate for at least 3 months with at least a weekly dose of 15 mg.
B: Inclusion Criteria:

* Active rheumatoid arthritis
* Inadequate response to stably dosed methotrexate

Exclusion Criteria:

* Current therapy with any DMARD or biologic other than methotrexate
C: Inclusion Criteria:

* The subject has a history of inadequate response to at least 1, but no more than 4, of the following DMARDs: sulfasalazine, injectable gold, methotrexate, leflunomide, cyclosporine, or a thiopurine derivative (azathioprine or 6-mercaptopurine)

Exclusion Criteria:

* Current Therapy With Any DMARD Or Biologic
D: Inclusion Criteria:

* The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria.
* The patient has active disease at both Screening and Baseline, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren method) \>28 mm in the local laboratory. 2. CRP \>7 mg/L in the central laboratory
* Patient had an inadequate response to at least one DMARD (traditional or biologic) due to lack of efficacy or toxicity.
* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
* Patient has washed out of all DMARDs other that antimalarials

Exclusion Criteria:

* Blood dyscrasias including confirmed: 1. Hemoglobin \<9 g/dL or Hematocrit \<30%; 2. White blood cell count \<3.0 x 109/L; 3. Absolute neutrophil count \<1.2 x 109/L; 4. Platelet count \<100 x 109/L
* History of any other autoimmune rheumatic disease other than Sjogren's syndrome
* No malignancy or history of malignancy.
* History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: PRALIMAP: Effectiveness Evaluation of Three Strategies of Prevention of Overweight and Obesity in Adolescents; a Cluster Randomised Controlled Trial
Brief Summary: The aim of this study is to compare the effectiveness of three public health intervention strategies to reduce weight excess and obesity prevalence among teenagers within the frame of a public health program aiming at promoting healthy eating and physical activity behaviors.


Options:
A: Inclusion Criteria:

* Participating schools need to meet the following eligibility criteria: (1) were within provincial jurisdiction, (2) had a minimum of 200 students per school, (3) offered grades 1 through 6.

Exclusion Criteria:

* Children will be excluded if consent was not received from parents or if they had a condition that limited participation in physical activity.
B: Inclusion Criteria:

* Schools must have at least one full classrooms for the 3rd year of preschool.
* The approval of boards of governors will be necessary to participate in the intervention and in the measurements at the beginning and end of academic year.
* Children's parents or legal representatives will sign an informed consent to participate.
* Children's parents will be invited to collaborate by filling in questionnaires with regard to family leisure habits, sleeping, eating and getting around town.

Exclusion Criteria:

* Children with severe Spanish language learning difficulties.
* Children with serious physical or mental disorders identified by parents or teachers that would impede participation in the programme's activities
* Children diagnoses of chronic disorders, such as heart disease, diabetes or asthma, which in the opinion of their paediatricians would prevent their participation in the programme's activities (MOVI-da10!).
C: Inclusion Criteria:

* Being student in the included public high school in Region of Lorraine (East of France) whatever the age

Exclusion Criteria:

* None
D: Inclusion Criteria:

* Healthy pupils of primary schools (5th grade) and secondary schools (10th grade)

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: PRALIMAP: Effectiveness Evaluation of Three Strategies of Prevention of Overweight and Obesity in Adolescents; a Cluster Randomised Controlled Trial
Brief Summary: The aim of this study is to compare the effectiveness of three public health intervention strategies to reduce weight excess and obesity prevalence among teenagers within the frame of a public health program aiming at promoting healthy eating and physical activity behaviors.


Options:
A: Inclusion Criteria:

* Students in grades 1-8 attending a participating school and receiving a school meal on a study day

Exclusion Criteria:

* Bringing a lunch from home on a study day or not eating lunch in the cafeteria on a study day
B: Inclusion Criteria:

* attenders at the relevant child care center

Exclusion Criteria:

* allergy or sensitivity to any test food
C: Inclusion Criteria:

* Being student in the included public high school in Region of Lorraine (East of France) whatever the age

Exclusion Criteria:

* None
D: Inclusion Criteria:

* Afterschool programs in Boston MA serving at least 40 children ages 5-12 years operating the full school year between September and June
* Afterschool programs serving a snack to children
* Children between the ages of 5 and 12 years

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: PRALIMAP: Effectiveness Evaluation of Three Strategies of Prevention of Overweight and Obesity in Adolescents; a Cluster Randomised Controlled Trial
Brief Summary: The aim of this study is to compare the effectiveness of three public health intervention strategies to reduce weight excess and obesity prevalence among teenagers within the frame of a public health program aiming at promoting healthy eating and physical activity behaviors.


Options:
A: Inclusion Criteria:

* Children ages 8-12 years of age
* At or above 85th BMI percentile
* Children must eat almost all meals with the exception of school lunch with the family.
* Overweight parent

Exclusion Criteria:

* Children who do not like the study foods, who are allergic to the study foods or who are on special diets and cannot consume the study foods.
* Families with children with a co-morbid psychiatric diagnosis or parents who are depressed, have schizophrenia, substance abuse or a history of eating disorders.
* The parent and child must not have any physical restrictions that would preclude them from making the requisite behavioral changes.
* Children must be able to read at a 3rd grade reading level and must be able to demonstrate the ability to keep dietary and activity records in a stimulated interview.
B: Inclusion Criteria:

* Client in food pantry

Exclusion Criteria:

* Minors
C: Inclusion Criteria:

* attenders at the relevant child care center

Exclusion Criteria:

* allergy or sensitivity to any test food
D: Inclusion Criteria:

* Being student in the included public high school in Region of Lorraine (East of France) whatever the age

Exclusion Criteria:

* None

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: PRALIMAP: Effectiveness Evaluation of Three Strategies of Prevention of Overweight and Obesity in Adolescents; a Cluster Randomised Controlled Trial
Brief Summary: The aim of this study is to compare the effectiveness of three public health intervention strategies to reduce weight excess and obesity prevalence among teenagers within the frame of a public health program aiming at promoting healthy eating and physical activity behaviors.


Options:
A: Inclusion Criteria

* High school freshman or sophomore
* Body mass index (BMI) from 16 through 23
* Member of Kaiser Permanente Northwest Health Plan
* Parent or guardian willing to participate

Exclusion Criteria

* Co-morbidity requiring a specific diet
* Medication which contraindicates consuming a high-fiber diet
* Life-threatening disease or other condition that would interfere with study participation
* Current or past medically or self-diagnosed eating disorder
* Current behaviors consistent with eating-related disorder
* Pregnancy
* Diagnosis of psychological disorder or difficulty within the past year
B: Inclusion Criteria:

* Any pupil attending years 7, 8, and 9 of a secondary comprehensive school in South Wales

Exclusion Criteria:

* Any pupil with an injury or illness that prevented them from taking part in any form of physical activity.
C: Inclusion Criteria:

* Healthy kindergarten children

Exclusion Criteria:

* Children with severe chronic disease (restricting physical activity)
D: Inclusion Criteria:

* Being student in the included public high school in Region of Lorraine (East of France) whatever the age

Exclusion Criteria:

* None

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: PRALIMAP: Effectiveness Evaluation of Three Strategies of Prevention of Overweight and Obesity in Adolescents; a Cluster Randomised Controlled Trial
Brief Summary: The aim of this study is to compare the effectiveness of three public health intervention strategies to reduce weight excess and obesity prevalence among teenagers within the frame of a public health program aiming at promoting healthy eating and physical activity behaviors.


Options:
A: Inclusion Criteria:

* • Any student studying the first academic year of secondary school (Enseñanza Secundaria Obligatoria, ESO) in the selected high schools.

Exclusion Criteria:

* No exclusion criteria.
B: Inclusion Criteria:

* Families with healthy adults and children

Exclusion Criteria:

* Various
C: Inclusion Criteria:

* Being student in the included public high school in Region of Lorraine (East of France) whatever the age

Exclusion Criteria:

* None
D: Inclusion Criteria:

* 10th grade high school student
* English speaking
* No chronic illnesses

Exclusion Criteria:

* Chronic medical illness

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk
Brief Summary: Patients with coronary heart disease (CHD) or CHD equivalent (e. g. diabetes mellitus) often have abnormalities in lipids (hypercholesterolemia). Besides, hypercholesterolemia is an evident risk factor for atherosclerosis. Hitherto, there are only few studies of patients with primary hypercholesterolemia where the combination therapy with statins (HMG-Co-reductase inhibitors) and ezetimib was investigated. This combination therapy should be more effective in reducing low density lipoprotein cholesterol (LDL-C) and total cholesterol levels compared to monotherapy.


Options:
A: Inclusion Criteria:

* Acute coronary syndrome
* Adults, 18 years and older

Exclusion Criteria:

* History of lipid lowering therapy less than 30 days before index event
* Pregnancy and nursing
* Subject younger than 18 years

Other inclusion and exclusion criteria may apply.
B: Inclusion Criteria:

* Patients with CHD or CHD equivalent with LDL 100-160 mg/dl
* Male or female sex
* Normal values of CK, AST and ALT
* Normal kidney function

Exclusion Criteria:

* CHD Stage III-IV
* St. p. myocardial infarction or coronary artery bypass grafting
* Pregnancy or breastfeeding
* Premenopausal women without certain contraception
* Known hypersensitivity to HMG-CoA reductase inhibitors or ezetimib
C: Inclusion Criteria:

* Dyslipidemia
* History of Myalgia

Exclusion Criteria:

* Previous treatment with fluvastatin
* Age \< 18 years

Other protocol-defined inclusion and exclusion criteria may apply.
D: Inclusion Criteria:

* Renal transplant recipients with stable renal function (plasma creatinine \< 200 µmol/L)
* Renal transplant recipients on an everolimus and fluvastatin based therapy for minimum 3 months prior to inclusion
* \> 18 years of age
* Male patient or female patient without childbearing potential (surgically sterilized or postmenopausal) or if female of childbearing potential; is not lactating, has a negative pregnancy test at screening and is willing to utilize an effective method of contraception throughout the study period and for 90 days following discontinuation of the study drugs
* Signed informed consent

Exclusion Criteria:

* Patients experiencing an acute rejection episode within 2 weeks before or after inclusion, whether proven by biopsy or not
* Patients with a known hypersensitivity to rosuvastatin
* Change in enzyme inducing or inhibiting drugs within the last 2 weeks prior to and throughout the study \[e.g. barbiturates, rifampicin, ketoconazole, erythromycin, cimetidine and similar drugs\]
* Pregnant or nursing mothers

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: I-START: Internet-based Strategic Transdisciplinay Approach to Risk Reduction And Treatment
Brief Summary: I-START is a randomized controlled trial that will evaluate the efficacy of an internet-based program of behavioural counseling for adaptive lifestyle change to subjects diagnosed with hypertension. I-START will be evaluated using objective outcome indices: systolic and diastolic blood pressure, pulse pressure, and markers of vagal-heart rate (HR) modulation and baroreflex sensitivity. The Heart and Stroke Foundation of Canada "Blood Pressure Action Plan(TM)" (BPAP) will be adminisered over a 4-month period, and evaluated in a 2 (Intervention vs. Wait list Control) X 2 (Baseline vs. Post-Intervention) factorial design, blocking for 3 recruitment sites (Toronto, London, the Grey Bruce region of Ontario, Canada), and stratified for sex and age group (45-59, 60-74 years).


Options:
A: Inclusion Criteria:

* Participation in a cardiovascular risk screening program
* 2 or more modifiable risk factors not on target:
* SBP \> 140 mmHg
* LDL-c \> 2.5 mmol/l
* Triglycerides \> 1.7 mmol/l
* BMI \> 25 kg/m2
* Diabetes Mellitus or fasting glucose \> 6.1 mmol/l
* Smoking

Exclusion Criteria:

* No internet access at home
* Unable to read and write Dutch
* Dependent in in daily activities (Ranking score \>=3)
* Life expectancy \< 2 years or an active malignant disease
B: Inclusion Criteria:

* Stage 1 OR Stage 2 hypertension
* 46 -74 years of age
* able to read \& write English or French
* living in private residence

Exclusion Criteria:

* Cardiovascular disease
* Major psychiatric disorder (e.g. psychosis)
* Dependence on Alcohol or Drugs with in past year
* Diabetes \>= 5 years
C: Inclusion Criteria:

* Stable coronary heart disease with CCS functional classification of angina class I-III
* Low self rated physical activity
* Condition after percutaneous coronary intervention \> 4 weeks until \< 26 weeks or \> 52 weeks after index percutaneous coronary intervention
* Residence \< 50 km radius of Mainz
* If treatment with betablockers or ivabradine then stable \> 4 weeks

Exclusion Criteria:

* Acute coronary sydnrome or myocardial infarction \< 8 weeks
* Coronary stenosis of the dominant vessel \> 25% or high grade stenosis of the left coronary artery
* Heart failure with left ventricular ejection fraction \< 40%
* NYHA III-IV
* Severe heart valve disorder
* Insulin dependent diabetes
* Orthopedic disorders or other disorders, which preclude regular physical activity
* Coronary artery bypass surgery \< 6 months before index PCI
* Severe obesity (BMI ≥ 40)
* Need for systemic immunosuppression with cortisone or methotrexate
* Kidney failure with need for dialysis
* Intake of nitrates \< 12 hours
D: Inclusion Criteria:

* regional Northern California KP employees

Exclusion Criteria:

* none

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?
Brief Summary: Bronchiectasis is a chronic chest condition which causes a persistent cough and frequent chest infections. One of the main forms of treatment is chest physiotherapy. Physiotherapy is thought to improve cough and help clear the airways of sticky sputum. Traditionally, physiotherapy techniques can be awkward, but recently a new device (a simple mouthpiece, called the Acapella device) has been developed to make physiotherapy practise easier. This study aims to assess how helpful regular physiotherapy using a new mouthpiece is in patients with severe bronchiectasis.


Options:
A: Inclusion Criteria:

1. COPD; patients defined by a history of cough, breathlessness and/ mucus/sputum production with lung function showing FEV1/FVC \<70% and FEV1\<80% predicted and \< 20% reversibility from baseline on administration of nebulised b2-agonist (Salbutamol 5mg)
2. Age 40-85 years
3. Mucus hypersecretion ( \> 25 ml/72 h collection)

Exclusion Criteria:

1. Chest wall deformity (i.e., kyphoscoliosis, Rib fractures)
2. Severe osteoporosis
3. Haemoptysis within the last 3 months
4. Thoracic or abdominal surgery within 3 months
5. Respiratory failure on non-invasive ventilator therapy
6. Tracheostomy or neck deformities
7. Neuro-muscular dysfunction or disability (i.e., Paralysis due to cerebrovascular disease) which may make it impossible to use the device safely
8. Congestive heart failure (decompensated)
9. Any other mucolytic therapy
10. Significant hiatus hernia or gastro-esophageal reflux disease
11. Recent myocardial infarction or unstable angina
B: Inclusion Criteria:

1. - Non Cystic Fibrosis bronchiectasis diagnosed by High Resolution Computed Tomographic
2. - Mean sputum production ≥ 15 ml /24h
3. - Clinical stability in the last 6 weeks
4. - Not carrying out regular chest physiotherapy
5. - Forced expiratory volume in 1 second ≥ 30% pred. ; Forced Vital Capacity ≥ 45% pred. and peak expiratory flow \>270 L/s

Exclusion Criteria:

1. - Smoker or non-smoker form less than 2 years
2. - Cystic fibrosis
3. - Active tuberculosis or sarcoidosis
C: Inclusion Criteria:

* Moderate and Severe Bronchiectasis
* No regular chest physiotherapy

Exclusion Criteria:

* Moderate or Severe COPD
D: Inclusion Criteria:

* Patients with moderate and severe bronchiectasis aged 18-75 will be recruited. Severity will be assessed radiologically by HRCT of the chest using the scoring method by Bhalla et al.

Exclusion Criteria:

* cystic fibrosis
* emphysema on HRCT chest and FEV1\<60% predicted
* active allergic bronchopulmonary aspergillosis or tuberculosis
* poorly controlled asthma
* pregnancy or breast feeding
* current smokers

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?
Brief Summary: Bronchiectasis is a chronic chest condition which causes a persistent cough and frequent chest infections. One of the main forms of treatment is chest physiotherapy. Physiotherapy is thought to improve cough and help clear the airways of sticky sputum. Traditionally, physiotherapy techniques can be awkward, but recently a new device (a simple mouthpiece, called the Acapella device) has been developed to make physiotherapy practise easier. This study aims to assess how helpful regular physiotherapy using a new mouthpiece is in patients with severe bronchiectasis.


Options:
A: Inclusion Criteria:

* Patients with moderate and severe bronchiectasis aged 18-75 will be recruited. Severity will be assessed radiologically by HRCT of the chest using the scoring method by Bhalla et al.

Exclusion Criteria:

* cystic fibrosis
* emphysema on HRCT chest and FEV1\<60% predicted
* active allergic bronchopulmonary aspergillosis or tuberculosis
* poorly controlled asthma
* pregnancy or breast feeding
* current smokers
B: Inclusion Criteria:

* Moderate and Severe Bronchiectasis
* No regular chest physiotherapy

Exclusion Criteria:

* Moderate or Severe COPD
C: Inclusion Criteria:

Bronchiectasis confirmed on High Resolution CT scan Clinical Bronchiectasis confirmed by a respiratory physician. Documented exacerbation within the last year. Independently mobile - i.e. able to undertake pulmonary rehabilitation

Exclusion Criteria:

* Inability to give informed consent to participate
* Age \<18 years
* Primary diagnosis of Chronic Obstructive Pulmonary Disease
* Significant comorbidity that would limit the ability to undertake pulmonary rehabilitation - i.e. Cerebrovascular, cardiovascular or musculoskeletal disease.
* Cystic Fibrosis
* Aortic aneurysm
* Recent myocardial infarction (within previous year)or unstable angina
D: Inclusion Criteria:

* Diagnosis of bronchiectasis (HRCT)
* Stable medical status for last 4 weeks
* History of 2 exacerbations in the last 2 years
* Dysnpoea on exertion (Modified Medical Research Council score \>1)

Exclusion Criteria:

* Concurrent diagnosis of COPD (physician diagnosis and history of 10 pack year smoking)
* Concurrent diagnosis of asthma (history of atopic disease and evidence of bronchodilator reversibility of 12% or 200ml in FEV1 or FVC)
* Concurrent diagnosis of Interstitial lung disease
* Concurrent diagnosis of Cystic Fibrosis
* Medical condition which could place patient at risk during exercise training (angina, neurological or orthopaedic condition)
* Prior completion of pulmonary rehabilitation within the last 12 months

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Pilot Cluster Randomised Controlled Trial of Flooring to Reduce Injuries From Falls in Elderly Care Units
Brief Summary: In hospitals, older people can fall and hurt themselves. The investigators want to see if a new type of flooring can help stop people hurting themselves as badly, if they accidentally fall.


Options:
A: Inclusion Criteria:

* all patients admitted to the study area on a participating elderly care ward

Exclusion Criteria:

* none.
B: Inclusion Criteria:

* over 60 years of age
* a goal of admission is to 'improve weight-bearing mobility or improve walking' as determined by either the admission referral or the treating therapist

Exclusion Criteria:

* specific medical restrictions that limit mobilisation (e.g. non weight bearing)
* if already enrolled in a different Randomised Controlled Trial
* previously enrolled in the current trial
* the primary reason for admission is awaiting a residential care placement
* the primary reason for admission is for carer training
C: Inclusion Criteria:

* Diagnosis of Dementia of the Alzheimer's Type
* Ambulatory, Outpatients who have an informant living/visiting at least 8 hours/week over 3-4 days.
* Presence of delusions, hallucinations, agitation impacting functioning and requiring medication treatment
* Agitation or psychotic symptoms began after signs or symptoms of dementia

Exclusion (prospective participants must not:)

* Be benefiting from psychotropic medication, antidepressants or anticonvulsants
* Be diagnosed with schizophrenia, schizoaffective disorder, delusional disorder or mood disorder with psychotic features.
* Have severe or unstable medical illness requiring active treatment
* Have hypersensitivity or intolerance of any of the study medications
D: Inclusion Criteria:

* Patient admitted to one of 16 study units at Methodist University Hospital

Answer: A